Jilin Aodong Pharmaceutical Group (000623) Fair Value & Analysis
Healthcare · CN · Market cap 21.3B CNY
Analysis
Jilin Aodong Pharmaceutical Group (000623) currently trades at ¥18.39, while our model-based Fair Value estimate is ¥6.83 — implying the stock looks roughly 62.9% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Jilin Aodong Pharmaceutical Group Co., Ltd. manufactures and sells pharmaceutical products in China. It provides various drugs, such as oral liquid solutions, injections, capsules, granules, pills, tablets, Chinese herbal medicines, powders, tonic medicines, syrups, and spirits, as well as enzymes, biochemical medicine, and plant chemical medicine. It is also involved in the highway construction and toll collection businesses; animal husbandry activities; manufacture of specialty chemicals; production and supply of heat and water; wholesale, retail, and distribution of medicines; production and sale of packaging materials; and information consulting and advertising design and production activities. In addition, the company offers pharmaceutical excipients and packaging materials; produces and sells enzyme stock solutions; ginseng and antler products; sells health care products; and processes edible agricultural products, etc. Jilin Aodong Pharmaceutical Group Co., Ltd. was founded i…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.